Angiogenic imbalance as a contributor to the pathophysiology of preeclampsia among black African women

References

• National Committee of Confidential Enquiries in Maternal Deaths. Saving mothers 2005–2007: Fourth report into maternal deaths in South Africa. Expanded executive summary. Pretoria: Department of Health, 2009. Available from: http://www0.sun.ac.za/ruralhealth/ukwandahome/rudasaresources2009/DOH/savingmothers%2005-07%5B1%5D.pdf
   Google Scholar
• Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785–99
   PubMed Web of Science ®Google Scholar
• Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005;308:1592–4
   PubMed Web of Science ®Google Scholar
• Buga GAB, Lumu SB. Hypertensive disorders of pregnancy at Umtata general hospital: perinatal and maternal outcomes. East Afr Med J 1999;76:217–22
   PubMed Web of Science ®Google Scholar
• Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011;123:2856–69
   PubMed Web of Science ®Google Scholar
• Redman CWG. Preeclampsia: a multi-stress disorder. Rev Med Interne 2011;32:S41–4
   PubMedGoogle Scholar
• Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta 2009;30:S32–7
   PubMed Web of Science ®Google Scholar
• Zhou Y, McMaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002;160:1405–23
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–83
   PubMed Web of Science ®Google Scholar
• Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125:911–19
   PubMed Web of Science ®Google Scholar
• Noori M, Donald AE, Angelakopoulou A, et al. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010;122:478–87
   PubMed Web of Science ®Google Scholar
• Thadlani R, Mtter WP, Wolf M. First trimester placental growth factor and soluble Fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004;89:770–5
   PubMed Web of Science ®Google Scholar
• Shibata E, Rajakumar A, Powers RW. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005;90:4895–903
   PubMed Web of Science ®Google Scholar
• Govender N, Naicker T, Moodley J. Maternal imbalance between pro-angiogenic and anti-angiogenic factors in Hiv-infected women with preeclampsia. Cardiovasc J Afr 2013;24:174–9
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J. Excess placental soluble FMS-like tyrosine kinase 1 (sFLT1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649–58
   PubMed Web of Science ®Google Scholar
• Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 2007;50:1142–7
   PubMed Web of Science ®Google Scholar
• Livingston JC, Chin R, Haddad B, et al. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol 2000;183:1554–7
   PubMed Web of Science ®Google Scholar
• Polliotti BM, Fry AG, Saller DN, et al. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003;101:1266–74
   PubMed Web of Science ®Google Scholar
• Wikstrom AK, Larsson A, Eriksson UJ, et al. Placental growth factor and soluble fms-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol 2007;109:1368–74
   PubMed Web of Science ®Google Scholar
• Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993;90:10705–9
   PubMed Web of Science ®Google Scholar
• Cindrova-Davies T, Sanders DA, Burton GJ, Charnock-Jones DS. Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling. Cardiovasc Res 2011;89:671–9
   PubMed Web of Science ®Google Scholar
• Verlohren S, Galingo A, Schlembach D, et al. An automated method for the determination of the sFLT1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010;202:161.e1–11
   PubMed Web of Science ®Google Scholar
• Hassan MF, Ali Rund NM, Salama AH. An elevated maternal plasma soluble fms-like tyrosine kinase-1 to placental growth factor ratio at midtrimester is a useful predictor for preeclampsia. Obstet Gynecol Int 2013;2013:202346
   PubMedGoogle Scholar
• Walsh CA., Baxi Mean arterial pressure and prediction of pre-eclampsia is better than diastolic or systolic pressures in low risk women, but is still only moderately effective. BMJ 2008;336:1079–80
   PubMed Web of Science ®Google Scholar
• Cnossen JS, Vollebregt KC, de Vrieze N, et al. Accuracy of mean arterial pressure and blood pressure measurements in predicting preeclampsia: systematic review and meta-analysis. BMJ 2008;336:1117–20
   PubMed Web of Science ®Google Scholar
• Lai J, Poon LCY, Bakalis S, et al. Systolic, diastolic and mean arterial pressure at 30–33 weeks in the prediction of preeclampsia. Fetal Diagn Ther 2013;33:173–81
   PubMed Web of Science ®Google Scholar
• Rolfo A, Many A, Racano A, et al. Abnormalities in oxygen sensing define early and late onset preeclampsia as distinct pathologies. PLoS One 2010;5:el3288
   Web of Science ®Google Scholar
• van der Merwe JL, Hall DR, Wright C, et al. Are early and late preeclampsia distinct subclasses of the disease-what does the placenta reveal? Hypertens Pregnancy 2010;29:457–67
   PubMed Web of Science ®Google Scholar
• Escudero C, Bertoglia P, Hernadez M, et al. Impaired A(2A) adenosine receptor/nitric oxide/VEGF signaling pathway in fetal endothelium during late- and early-onset preeclampsia. Purinergic Signal 2013;9:215–26
   PubMed Web of Science ®Google Scholar
• Bahado-Singh RO, Akolekar R, Mandal R, et al. First-trimester metabolomic detection of late-onset preeclampsia. Am J Obstet Gynecol 2012;25:1840–7
   Google Scholar
• Masuyama H, Segawa T, Sumida Y, et al. Different profiles of circulating angiogenic factors and adipocytokines between early- and late-onset preeclampsia. BJOG 2009;117:314–20
   PubMed Web of Science ®Google Scholar
• Ohkuchi A, Hirashima C, Matsubara S, et al. Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res 2007;30:151–9
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Kim YM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of preeclampsia. J Matern Fetal Neonatal Med 2005;17:3–18
   PubMed Web of Science ®Google Scholar
• Crispi F, Dominguez C, Llurba E, et al. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 2006;195:201–7
   PubMed Web of Science ®Google Scholar
• Weiler J, Tong S, Palmer KR. Is fetal growth restriction associated with a more severe maternal phenotype in the setting of early onset pre-eclampsia? A retrospective study. PLoS One 2011;6:e26937
   PubMedGoogle Scholar
• Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre eclampsia and by small-for gestational age infants. Br J Obstet Gynaecol 1986;93:1049–59
   PubMedGoogle Scholar
• Lin S, Shimizu I, Suehara N, et al. Uterine artery Doppler velocimetry in relation to trophoblast migration into the myometrium of the placental bed. Obstet Gynecol 1995;85:760–5
   PubMed Web of Science ®Google Scholar
• Li H, Gu B, Zhang Y, et al. Hypoxia induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta 2005;26:210–17
   PubMed Web of Science ®Google Scholar
• Lash GE, Taylor CM, Trew AJ, et al. Vascular endothelial growth factor and placental growth factor release in cultured trophoblast cells under different oxygen tensions. Growth Factors 2002;20:189–96
   PubMed Web of Science ®Google Scholar
• Cross JC. The genetics of preeclampsia: a feto-placental or maternal problem? Clin Genet 2003;64:96–103
   PubMed Web of Science ®Google Scholar
• Papageorghiou AT, Yu CK, Bindra R, et al. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 2001;18:441–9
   PubMed Web of Science ®Google Scholar
• Papp E, Loutfy M, Yudin M, et al. Angiogenesis and adverse pregnancy outcomes in women with HIV: the AAPH study. 3rd international workshop on HIV and women; 2013 Jan 14–15; Toronto, Canada. Oral Abstract 0012. Available from: http://regist2.virology-education.com/2013/3hw/docs/21_Serghides.pdf
   Google Scholar
• Kalumba VMS, Moodley J, Naidoo TD. Is the prevalence of pre-eclampsia affected by HIV/AIDS? A retrospective case-control study. Cardiovasc J Afr 2013;24:24–7
   PubMed Web of Science ®Google Scholar